Intelligence / Healthtech / New Clinical Trials / Zi Diligence Biocenter
Zi Diligence Biocenter
6 Nov 2026: Trial registered · An Open-label, Randomized, Single Oral Dose, Two-period, Two-sequence, Two-way, Crossover Bioequivalence Study on Healthy Adult Male Participants Under Fed Conditions to Compare, Test Product Palbociclib-EVAPHARMA 125 mg Hard Gelatin Capsule, Versus the Reference Product Ibrance™125 mg Capsules. Recorded in the ClinicalTrials.gov (US National Library of Medicine).
- Posted
- 6 Nov 2026
- Title
- An Open-label, Randomized, Single Oral Dose, Two-period, Two-sequence, Two-way, Crossover Bioequivalence Study on Healthy Adult Male Participants Under Fed Conditions to Compare, Test Product Palbociclib-EVAPHARMA 125 mg Hard Gelatin Capsule, Versus the Reference Product Ibrance™125 mg Capsules
- Conditions
- Bioequivalence, Male
- Phase
- Phase 1
- Study Type
- Interventional
- Status
- Completed
- Countries
- Egypt
- Country
- Egypt
- Reference
- NCT07922564
- Location
- Egypt
A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.
- United States leads with 192 of 777, then China (171).
- 777 added in the 30 days to 18 Nov 2026.
Find the decision makers at Zi Diligence Biocenter
AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.
Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.